'Ist 3' diaporamas de présentation

IST-3: Progress, continuing uncertainties in thrombolysis and challenges

IST-3: Progress, continuing uncertainties in thrombolysis and challenges. Peter Sandercock & Richard Lindley Co-chief investigators, IST-3. IST-3 Collaborators Meeting, Glasgow 30 th May 2007. Recruitment. Recruitment = 809 patients from 83 centres in 9 countries. Patient no 801

539 views • 41 slides

Thrombolysis for acute ischaemic stroke 1: why do we still need to do randomised trials & IST3?

641 views • 41 slides

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke

Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke. Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of Minnesota Great Lakes Regional Stroke Network October 8, 2009. Disclosures.

743 views • 34 slides

IST-3 Collaborators meeting

450 views • 32 slides

Third International Stroke Trial (IST-3): response to ECASS-3 results

Third International Stroke Trial (IST-3): response to ECASS-3 results. Professor Peter Sandercock, University of Edinburgh. Collaborators Meeting Vienna 26 th September 2008. Outline. At a population level, between 1% and 3% of all ischaemic strokes are treated

538 views • 28 slides

What do the IST-3 results mean for the elderly patient with acute stroke?

What do the IST-3 results mean for the elderly patient with acute stroke?. Westmead Hospital Clinical School | George Institute for Global Health. Richard I Lindley | Professor. Potential Financial Conflicts of Interest.

345 views • 18 slides

Peter Sandercock On behalf of the IST-3 Collaborative Group UK Stroke Forum

Thrombolysis for stroke & remaining uncertainties after ECASS3; clues from the type of patients recruited in IST-3. Peter Sandercock On behalf of the IST-3 Collaborative Group UK Stroke Forum Glasgow, 3 rd December 2009. Uncertainties* about thrombolysis in acute ischaemic stroke.

282 views • 15 slides

23 rd May 2012 Lisbon

The third international stroke trial (IST-3) main results: primary and secondary outcomes among 3035 patients. The IST3 collaborative group - 156 hospitals in UK, Poland, Italy, Sweden, Norway, Australia, Portugal, Belgium, Austria, Switzerland, Canada, Mexico.

218 views • 15 slides

Baseline characteristics of the 3035 patients recruited in IST3

Baseline characteristics of the 3035 patients recruited in IST3. Peter Sandercock On behalf of the IST3 collaborative group UKSF Glasgow 30th November 2011. These results published today www.trialsjournal.com. Main features of IST - 3.

261 views • 13 slides